Physicochemical Properties
Molecular Formula | C50H94N20O22S |
Molecular Weight | 1359.47 |
Exact Mass | 502.249 |
CAS # | 96736-11-7 |
PubChem CID | 131668562 |
Appearance | White to off-white solid powder |
Density | 1.9±0.1 g/cm3 |
Index of Refraction | 1.790 |
LogP | -5.12 |
Hydrogen Bond Donor Count | 12 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 11 |
Heavy Atom Count | 40 |
Complexity | 897 |
Defined Atom Stereocenter Count | 9 |
SMILES | C1[C@H]([C@@H]2[C@@H](C(=O)N1)N=C(N2)N[C@H]3[C@@H]([C@@H]([C@H]([C@H](O3)CO)OC(=O)N)O)NC(=O)C[C@H](CCCN)N)O.OS(=O)(=O)O |
InChi Key | UDVWKDBCMFLRQW-TWRCRAKCSA-N |
InChi Code | InChI=1S/C19H34N8O8.H2O4S/c20-3-1-2-7(21)4-10(30)24-13-14(31)15(35-18(22)33)9(6-28)34-17(13)27-19-25-11-8(29)5-23-16(32)12(11)26-19;1-5(2,3)4/h7-9,11-15,17,28-29,31H,1-6,20-21H2,(H2,22,33)(H,23,32)(H,24,30)(H2,25,26,27);(H2,1,2,3,4)/t7-,8+,9+,11+,12-,13+,14-,15-,17+;/m0./s1 |
Chemical Name | [(2R,3R,4S,5R,6R)-6-[[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3S)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate;sulfuric acid |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
ln Vitro | Nourseothricin sulfate resistance in E. coli can make resistant bacteria susceptible by removing their outer membrane resistance. Nourseothricin sulfate can enter the cell through porin pores and cross the outer membrane. Previous research had demonstrated that nourseothricin sulfate may open up specific channels in the outer membrane that allowed the drug to enter the cell wall. Nonetheless, there are signs that resistant strains with inactivated Nourseothricin sulfate acetyltransferase may have an extra defense mechanism in the form of a weakened outer membrane. |
ln Vivo | Nephrotoxicity symptoms may appear after the administration of nourseothricin sulfate, as the kidneys are the organs that preferentially eliminate the medication. Using renal cortical slices, tests were conducted under different experimental settings to assess the renal processing of Nourseothricin sulfate. Nourseothricin has no effect on the renal tubular transport system of the organic anion (para-aminohippurate, PAH) following in vivo administration. Renal cortical sections had a significant concentration of nourseothricin sulfate accumulation. Nourseothricin sulfate buildup was unaffected by probenecid, trihydroxyaminomethane, or simultaneous administration of PAH or nitrogen atmosphere, in contrast to PAH accumulation. There are no age-related variations in the buildup of Nourseothricin sulfate [4]. |
References |
[1]. Resistance of Escherichia coli to nourseothricin (streptothricin): sensitization of resistant strains by abolition of its outer membrane resistance. Zentralbl Bakteriol. 1992 Jan;276(2):143-51. [2]. Genetic manipulation of Fonsecaea pedrosoi using particles bombardment and Agrobacterium mediated transformation. Microbiol Res. 2018 Mar;207:269-279. [3]. Plant-Growth Promotion and Biocontrol Properties of Three Streptomyces spp. Isolates to Control Bacterial Rice Pathogens. Front Microbiol. 2019 Feb 25;10:290. [4]. Renal handling of nourseothricin. Pharmazie. 1988 Mar;43(3):200-2. |
Solubility Data
Solubility (In Vitro) | H2O : 250 mg/mL (183.90 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (73.56 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.7356 mL | 3.6779 mL | 7.3558 mL | |
5 mM | 0.1471 mL | 0.7356 mL | 1.4712 mL | |
10 mM | 0.0736 mL | 0.3678 mL | 0.7356 mL |